Navegar por autor "Pérez Encinas, Manuel Mateo"

A good adherence to ELN 09 recommendations in chronic myeloid leukemia (CML) treatment with imatinib, is associated with better outcomes in patients treated outside clinical trials

2012- Pérez Encinas, Manuel Mateo

A prognostic index for patients with refractory or in first relapsed acute myeloid leukemia treated with FLAG-IDA or flago-IDA

2014- Pérez Encinas, Manuel Mateo

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

2023- Mosquera Orgueira, Adrián; Díaz Arias, José; Serrano Martín, R.; Portela Piñeiro, V.; Cid López, Miguel; [et al.]

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

2023- Mosquera Orgueira, Adrián; Díaz Arias, José; Serrano Martín, R.; Portela Piñeiro, V.; Cid López, Miguel; [et al.]

ACUTE MYELOID LEUKEMIA IN PATIENTS 70 AND ABOVE. AZACITIDINE VERSUS INTENSIVE CHEMOTHERAPY

2014- Debén Ariznavarreta, Guillermo; Pérez Encinas, Manuel Mateo

Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia

2023- Alvarez-Larrán, A.; Cuevas, B.; Velez, P.; Noya Pereira, María Soledad; Caballero-Navarro, G.; [et al.]

Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia

2023- Alvarez-Larrán, A.; Cuevas, B.; Velez, P.; Noya Pereira, María Soledad; Caballero-Navarro, G.; [et al.]

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study

2020- De Stefano, V.; Ghirardi, A.; Masciulli, A.; Carobbio, A.; Palandri, F.; [et al.]

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study

2020- De Stefano, V.; Ghirardi, A.; Masciulli, A.; Carobbio, A.; Palandri, F.; [et al.]

The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution

2019- MOSQUERA ORGUEIRA, ADRIAN; Antelo Rodríguez, Beatriz; Alonso Vence, Natalia; Díaz Arias, José; Díaz Varela, Nicolás; [et al.]

Azacitidine as front-line therapy in AML: Results from spanish national registry. Alma study investigators

2012- Debén Ariznavarreta, Guillermo; Pérez Encinas, Manuel Mateo

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction

2015- Debén Ariznavarreta, Guillermo; Pérez Encinas, Manuel Mateo

Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score

2015- Debén Ariznavarreta, Guillermo; Pérez Encinas, Manuel Mateo

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

2022- Labrador, J.; Martínez-Cuadrón, D.; De La Fuente, A.; Rodríguez-Veiga, R.; Serrano, J.; [et al.]

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

2020- Sobas, M.; Rodriguez-Veiga, R.; Vellenga, E.; Paluszewska, M.; De la Serna, J.; [et al.]

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

2020- Sobas, M.; Rodriguez-Veiga, R.; Vellenga, E.; Paluszewska, M.; De la Serna, J.; [et al.]

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

2022- Martínez-Cuadrón, D.; Serrano, J.; Mariz, J.; Gil, C.; Tormo, M.; [et al.]

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

2023- Bernal, T.; Moreno, A.F.; de LaIglesia, A.; Benavente, C.; García-Noblejas, A.; [et al.]

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

2023- Bernal, T.; Moreno, A.F.; de LaIglesia, A.; Benavente, C.; García-Noblejas, A.; [et al.]

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.

2011- Pérez Encinas, Manuel Mateo; Montesinos, Pau; Rayón, Chelo; Vellenga, Edo; Brunet, Salut; [et al.]

O repositorio dixital RUNA

Navegar por autor "Pérez Encinas, Manuel Mateo"

A good adherence to ELN 09 recommendations in chronic myeloid leukemia (CML) treatment with imatinib, is associated with better outcomes in patients treated outside clinical trials ﻿

A prognostic index for patients with refractory or in first relapsed acute myeloid leukemia treated with FLAG-IDA or flago-IDA ﻿

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma ﻿

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma ﻿

ACUTE MYELOID LEUKEMIA IN PATIENTS 70 AND ABOVE. AZACITIDINE VERSUS INTENSIVE CHEMOTHERAPY ﻿

Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia ﻿

Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia ﻿

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study ﻿

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study ﻿

The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution ﻿

Azacitidine as front-line therapy in AML: Results from spanish national registry. Alma study investigators ﻿

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction ﻿

Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score ﻿

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry ﻿

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols ﻿

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols ﻿

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia ﻿

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry ﻿

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry ﻿

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. ﻿

A good adherence to ELN 09 recommendations in chronic myeloid leukemia (CML) treatment with imatinib, is associated with better outcomes in patients treated outside clinical trials

A prognostic index for patients with refractory or in first relapsed acute myeloid leukemia treated with FLAG-IDA or flago-IDA

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

ACUTE MYELOID LEUKEMIA IN PATIENTS 70 AND ABOVE. AZACITIDINE VERSUS INTENSIVE CHEMOTHERAPY

Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia

Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study

The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution

Azacitidine as front-line therapy in AML: Results from spanish national registry. Alma study investigators

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction

Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.